FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β-catenin signaling cascade via FGFR4 activation

Oncotarget

Volumn 7, Issue 12, 2016, Pages 13575-13586

  Zhao, Huakan ^a   Lv, Fenglin ^a   Liang, Guizhao ^a   Huang, Xiaobin ^a   Wu, Gang ^b   Zhang, Wenfa ^a   Yu, Le ^a   Shi, Lei ^a   Teng, Yong ^a  

^a CHONGQING UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

E cadherin; EMT; FGF19; FGFR4; GSK3 catenin

Indexed keywords

BETA CATENIN; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; UVOMORULIN; CTNNB1 PROTEIN, HUMAN; FGF19 PROTEIN, HUMAN; FGFR4 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; TUMOR MARKER;

ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS INHIBITION; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; PROTEIN DEPLETION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR INVASION; APOPTOSIS; CASE CONTROL STUDY; CELL MOTION; CELL PROLIFERATION; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR CELL CULTURE;

APOPTOSIS; BETA CATENIN; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLAST GROWTH FACTORS; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; LIVER NEOPLASMS; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84971667932     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6185     Document Type: Article

References (43)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379:1245-1255.
2. Sherman M. Recurrence of hepatocellular carcinoma.The New England journal of medicine. 2008; 359:2045-2047.
3. Shimada K, Sakamoto Y, Esaki M, Kosuge T,Morizane C, Ikeda M, Ueno H, Okusaka T, Arai Y, Takayasu K. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma. Annals of surgical oncology. 2007; 14:2337-2347.
4. van Zijl F, Zulehner G, Petz M, Schneller D, Kornauth C, Hau M, Machat G, Grubinger M, Huber H, Mikulits W. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future oncology. 2009; 5:1169-1179.
5. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature reviews Cancer. 2009; 9:265-273.
6. Zhai B, Yan HX, Liu SQ, Chen L, Wu MC, Wang HY. Reduced expression of E-cadherin/catenin complex in hepatocellular carcinomas. World journal of gastroenterology. 2008; 14:5665-5673.
7. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Current opinion in cell biology. 2005; 17: 548-558.
8. Yang MH, Chen CL, Chau GY, Chiou SH, Su CW,Chou TY, Peng WL, Wu JC. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology. 2009; 50:1464-1474.
9. Pez F, Lopez A, Kim M, Wands JR, Caron de Fromentel C, Merle P. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol. 2013; 59:1107-1117.
10. Suarez MI, Uribe D, Jaramillo CM, Osorio G, Perez JC, Lopez R, Hoyos S, Hainaut P, Pineau P, Navas MC. Wnt/beta-catenin signaling pathway in hepatocellular carcinomas cases from Colombia. Annals of hepatology. 2015; 14:64-74.
11. Stamos JL, Weis WI. The beta-catenin destruction complex. Cold Spring Harbor perspectives in biology. 2013; 5:a007898.
12. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012; 149:1192-1205.
13. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R.beta-catenin is a target for the ubiquitin-proteasome pathway. The EMBO journal. 1997; 16:3797-3804.
14. Hur EM, Zhou FQ. GSK3 signalling in neural development. Nature reviews Neuroscience. 2010; 11:539-551.
15. Xie MH, Holcomb I, Deuel B, Dowd P, Huang A,Vagts A, Foster J, Liang J, Brush J, Gu Q, Hillan K, Goddard A, Gurney AL. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine. 1999; 11:729-735.
16. Jones S. Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm. 2008; 5:42-48.
17. Harmer NJ, Pellegrini L, Chirgadze D, Fernandez-Recio J and Blundell TL. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry. 2004; 43:629-640.
18. Jones SA. Physiology of FGF15/19. Adv Exp Med Biol. 2012; 728:171-182.
19. Uriarte I, Latasa MU, Carotti S, Fernandez-Barrena MG, Garcia-Irigoyen O, Elizalde M, Urtasun R, Vespasiani-Gentilucci U, Morini S, de Mingo A, Mari M, Corrales FJ, Prieto J, Berasain C, Avila MA. Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. Int J Cancer. 2015; 136:2469-2475.
20. Sawey ET, Chanrion M, Cai C, Wu G, Zhang J, Zender L, Zhao A, Busuttil RW, Yee H, Stein L, French DM, Finn RS, Lowe SW, Powers S. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer cell. 2011; 19:347-358.
21. Buhmeida A, Dallol A, Merdad A, Al-Maghrabi J,Gari MA, Abu-Elmagd MM, Chaudhary AG, Abuzenadah AM, Nedjadi T, Ermiah E, Al-Thubaity F, Al-Qahtani MH. High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35:2817-2824.
22. Feng S, Dakhova O, Creighton CJ, Ittmann M. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res. 2013; 73:2551-2562.
23. Xu YF, Yang XQ, Lu XF, Guo S, Liu Y, Iqbal M,Ning SL, Yang H, Suo N, Chen YX. Fibroblast growth factor receptor 4 promotes progression and correlates Cross Mark to poor prognosis in cholangiocarcinoma. Biochemical and biophysical research communications. 2014; 446:54-60.
24. Miura S, Mitsuhashi N, Shimizu H, Kimura F, Yoshidome H, Otsuka M, Kato A, Shida T, Okamura D, Miyazaki M. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC cancer. 2012; 12.
25. Hyeon J, Ahn S, Lee JJ, Song DH, Park CK. Expression of Fibroblast Growth Factor 19 Is Associated with Recurrence and Poor Prognosis of Hepatocellular Carcinoma. Digest Dis Sci. 2013; 58:1916-1922.
26. Desnoyers L, Pai R, Ferrando R, Hotzel K, Le T, Ross J, Carano R, D'Souza A, Qing J, Mohtashemi I, Ashkenazi A, French D. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene. 2008; 27:85-97.
27. Lin BC, Desnoyers LR. FGF19 and cancer. Adv Exp Med Biol. 2012; 728:183-194.
28. Pai R, Dunlap D, Qing J, Mohtashemi I, Hotzel K, French DM. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res. 2008; 68:5086-5095.
29. Pelaez-Garcia A, Barderas R, Torres S, Hernandez-Varas P, Teixido J, Bonilla F, de Herreros AG, Casal JI. FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer. PloS one. 2013; 8:e63695.
30. Brabletz T. EMT, MET in metastasis: where are the cancer stem cells? Cancer cell. 2012; 22:699-701.
31. Gao ZH, Tretiakova MS, Liu WH, Gong C, Farris PD, Hart J. Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma. Modern pathology. 2006; 19:533-540.
32. Duffy DJ, Krstic A, Schwarzl T, Higgins DG, Kolch W. GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling. Molecular cancer therapeutics. 2014; 13:454-467.
33. Li YS, Liu M, Nakata Y, Tang HB. beta-catenin accumulation in nuclei of hepatocellular carcinoma cells up-regulates glutathione-s-transferase M3 mRNA. World journal of gastroenterology. 2011; 17:1772-1778.
34. Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim SG, Ullrich A. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol. 2009; 50:118-127.
35. Wu X, Ge H, Lemon B, Vonderfecht S, Weiszmann J, Hecht R, Gupte J, Hager T, Wang Z, Lindberg R, Li Y. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. The Journal of biological chemistry. 2010; 285:5165-5170.
36. French DM, Lin BC, Wang MP, Adams C, Shek T, Hotzel K, Bolon B, Ferrando R, Blackmore C, Schroeder K, Rodriguez LA, Hristopoulos M, Venook R, Ashkenazi A, Desnoyers LR. Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models. PLoS One. 2012; 7:e36713.
37. Ahn SM, Jang SJ, Shim JH, Kim D, Hong SM, Sung CO, Baek D, Haq F, Ansari AA, Lee SY, Chun SM, Choi S, Choi HJ, Kim J, Kim S, Hwang S, et al. Genomic Portrait of Resectable Hepatocellular Carcinomas: Implications of RB1 and FGF19 Aberrations for Patient Stratification. Hepatology. 2014; 60:1972-1982.
38. Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013; 144:512-527.
39. Liu R, Li J, Xie K, Zhang T, Lei Y, Chen Y, Zhang L, Huang K, Wang K, Wu H, Wu M, Nice EC, Huang C, Wei Y. FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. Cancer Res. 2013; 73:5926-5935.
40. Lee YC, Gajdosik MS, Josic D, Clifton JG, Logothetis C, Yu-Lee LY, Gallick GE, Maity SN, Lin SH. Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment. Molecular & cellular proteomics: MCP. 2015; 14:471-483.
41. Yang X, Li L, Huang Q, Xu W, Cai X, Zhang J, Yan W, Song D, Liu T, Zhou W, Li Z, Yang C, Dang Y, Xiao J. Wnt signaling through Snail1 and Zeb1 regulates bone metastasis in lung cancer. American journal of cancer research. 2015; 5:748-755.
42. He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. Journal of the American Society of Nephrology. 2009; 20:765-776.
43. Mellor HR. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations. Liver Int. 2014; 34:E1-E9.